Atrial FibrillationAfMAZE EPNCT01769287
EP Study of Patients Who Have Received Left Atrial Ablation Using High Intensity Focused Ultrasound
An observational study of Atrial Fibrillation, run by University Hospital Plymouth NHS Trust at 1 site in United Kingdom.
Trial summary
The purpose of this study is to check if at 1 year after surgical ablation the electrical impulses that cause atrial fibrillation (AF) are still blocked from being able to get into the heart. Hypothesis Conduction block and ganglionic destruction are required for freedom from AF. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation
- How many people
- 20 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Jan 2013to Sep 2013
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Secondary care clinic - Patients who have undergone an Epicor HIFU ablation >12 months ago
Who may be able to join
- All patients will be screened prior to enrollment in the study. The following inclusion criteria will apply to all prospective candidates:
- Patients who have undergone an Epicor HIFU ablation >12 months ago
- Patients having the ability to fully comply with the study requirements
- Patients who have given written fully informed consent to participate in the study
Who cannot join
- Patients will be excluded from the study if they meet any of the following criteria:
- Patients who are unable to give full informed consent for the present sub-study.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Plymouth Hosptals NHS Trust
Plymouth, Devon, PL6 8BX
About this study
Official title: EP Study at >1 Year to Evaluate the Presence of Conduction Block Across the Cinch Line in Patients Who Have Received Left Atrial Ablation Using High Intensity Focused Ultrasound(HIFU)
The purpose of this study is to check if at 1 year after surgical ablation the electrical impulses that cause atrial fibrillation (AF) are still blocked from being able to get into the heart.
Hypothesis Conduction block and ganglionic destruction are required for freedom from AF.
Read the detailed description
Atrial fibrillation (AF) is an increasing common disease. It ranges from being asymptomatic to a highly disabling condition with a severe impact on quality of life. It is termed paroxysmal (PAF) when an episode lasts less than 7 days, persistent (PerAF) when it lasts more than 7 days and needs intervention and permanent (PermAF) when it is accepted as the long term rhythm. Treatment is based on symptom control and the prevention of complications such as stroke. When an attempt is made to restore normal sinus rhythm (NSR), this is termed 'rhythm control'.
Treatments for rhythm control of AF can be broadly divided into pharmacological and ablative. Ablative techniques1 are typically performed percutaneously using catheter-based technology (minimally invasive), though some surgical techniques also exist. They work on the principle that performing a series of 'burns' (scar) in appropriate places can prevent abnormal electrical signals forming and propagating within the heart.
The problem of atrial fibrillation is vast. Prevalence ranges from 0.2% in the 45-54 age group, rising to 8% in the over 75s. Though the majority of patients can be satisfactorily treated medically, in a not insignificant portion, the drugs are either poorly tolerated or are ineffective. For these patients, the United Kingdom (UK) NICE guidelines recommend consideration of an ablation procedure. In Derriford hospital alone we see approximately 14 patients suitable for AF ablation in a typical month.
The electrophysiological consequences of ablation are unclear. It is not known whether complete bidirectional electrical block across the ablation lines isolating the pulmonary antral region from the rest of the left atrium is a prerequisite for long-term cure of Atrial Fibrillation (AF). Studies in canine models of atrial fibrillation have suggested that incomplete lines of block can be as effective in reducing AF burden as complete lines, however the limited number of follow up studies in humans that have assessed both patients with recurrent AF and also asymptomatic patients who appear to have been cured by catheter ablation have suggested that complete electrical isolation of the pulmonary veins is necessary for a cure. Advocates for ablation without assessing electrical block argue success rates in humans are similar whether circumferential electrical isolation of the pulmonary veins is achieved or not. Assessing freedom from AF and correlating it with the presence or absence of complete bidirectional electrical block, intra-operatively and at post one-year follow-up, will allow a further understanding of the mechanisms determining the success or failure of AF ablation therapies. This will be very important in knowing how to treat patients in whom AF still occurs and will guide the approach to subsequent interventions.
Though there is a small risk involved in this study, the question it addresses will have a significant impact on the development of future AF ablation techniques. Within this group, over 300 separate ablation procedures have been performed with no deaths or significant complications. Previous groups have published trans-septal observational studies in humans demonstrating that previous ethics committees have appreciated the importance of such work. The 2012 Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) consensus statement on catheter and surgical ablation for AF has recently highlighted the need for novel trial designs demonstrating 'durability of pulmonary vein isolation' with a repeat diagnostic electrophysiological study.
This trial will therefore increase our understanding of the electrophysiological properties associated with successful ablation and how Atrial Fibrillation ablation and the HIFU procedure work.
- Conditions
- Atrial Fibrillation
- Keywords
- Atrial fibrillation, Electrophysiological Assessment, 12 months post-operatively, High Intensity Ultrasound
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Surgical operation | The study aims to recruit a total of 20 patients, 10 of whom have AF and 10 who do not. |
What is being measured
The primary outcome is the main question the study is designed to answer.
To document the incidence of 1 year post ablation bidirectional conduction block through the pulmonary venous cinch and mitral lines
Incidence of conduction block post ablation at 12 months across the pulmonary venous and mitral lines.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2013 (estimated)
- Study startJan 2013
- Primary completionSep 2013
- Study completionSep 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital Plymouth NHS Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Abbott Medical Devices
- Responsible party
- Sponsor
- Investigators
- Malcolm Dalrymple-Hay, MB BS, PhD, Principal investigator, University Hospital Plymouth NHS Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01769287
- Sponsor's protocol ID
- AF08004AF
- Acronym
- AfMAZE EP
- Status last verified
- Sep 2013
- First submitted
- 1 Nov 2012
- Last updated
- 19 Sep 2017
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Sep 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- EP Study at >1 Year to Evaluate the Presence of Conduction Block Across the Cinch Line in Patients Who Have Received Left Atrial Ablation Using High Intensity Focused Ultrasound(HIFU)
- ClinicalTrials.gov ID
- NCT01769287
- Acronym / sponsor ID
- AfMAZE EP / AF08004AF
- Conditions
- Atrial Fibrillation
- Keywords
- Atrial fibrillation, Electrophysiological Assessment, 12 months post-operatively, High Intensity Ultrasound
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University Hospital Plymouth NHS TrustUniversity, hospital or other
- Collaborators
- Abbott Medical Devices
- Study start
- Jan 2013
- Primary completion
- Sep 2013 (actual)
- Study completion
- Sep 2013 (actual)
- First posted
- 16 Jan 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to check if at 1 year after surgical ablation the electrical impulses that cause atrial fibrillation (AF) are still blocked from being able to get into the heart.
Hypothesis Conduction block and ganglionic destruction are required for freedom from AF.
Detailed description
Atrial fibrillation (AF) is an increasing common disease. It ranges from being asymptomatic to a highly disabling condition with a severe impact on quality of life. It is termed paroxysmal (PAF) when an episode lasts less than 7 days, persistent (PerAF) when it lasts more than 7 days and needs intervention and permanent (PermAF) when it is accepted as the long term rhythm. Treatment is based on symptom control and the prevention of complications such as stroke. When an attempt is made to restore normal sinus rhythm (NSR), this is termed 'rhythm control'.
Treatments for rhythm control of AF can be broadly divided into pharmacological and ablative. Ablative techniques1 are typically performed percutaneously using catheter-based technology (minimally invasive), though some surgical techniques also exist. They work on the principle that performing a series of 'burns' (scar) in appropriate places can prevent abnormal electrical signals forming and propagating within the heart.
The problem of atrial fibrillation is vast. Prevalence ranges from 0.2% in the 45-54 age group, rising to 8% in the over 75s. Though the majority of patients can be satisfactorily treated medically, in a not insignificant portion, the drugs are either poorly tolerated or are ineffective. For these patients, the United Kingdom (UK) NICE guidelines recommend consideration of an ablation procedure. In Derriford hospital alone we see approximately 14 patients suitable for AF ablation in a typical month.
The electrophysiological consequences of ablation are unclear. It is not known whether complete bidirectional electrical block across the ablation lines isolating the pulmonary antral region from the rest of the left atrium is a prerequisite for long-term cure of Atrial Fibrillation (AF). Studies in canine models of atrial fibrillation have suggested that incomplete lines of block can be as effective in reducing AF burden as complete lines, however the limited number of follow up studies in humans that have assessed both patients with recurrent AF and also asymptomatic patients who appear to have been cured by catheter ablation have suggested that complete electrical isolation of the pulmonary veins is necessary for a cure. Advocates for ablation without assessing electrical block argue success rates in humans are similar whether circumferential electrical isolation of the pulmonary veins is achieved or not. Assessing freedom from AF and correlating it with the presence or absence of complete bidirectional electrical block, intra-operatively and at post one-year follow-up, will allow a further understanding of the mechanisms determining the success or failure of AF ablation therapies. This will be very important in knowing how to treat patients in whom AF still occurs and will guide the approach to subsequent interventions.
Though there is a small risk involved in this study, the question it addresses will have a significant impact on the development of future AF ablation techniques. Within this group, over 300 separate ablation procedures have been performed with no deaths or significant complications. Previous groups have published trans-septal observational studies in humans demonstrating that previous ethics committees have appreciated the importance of such work. The 2012 Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) consensus statement on catheter and surgical ablation for AF has recently highlighted the need for novel trial designs demonstrating 'durability of pulmonary vein isolation' with a repeat diagnostic electrophysiological study.
This trial will therefore increase our understanding of the electrophysiological properties associated with successful ablation and how Atrial Fibrillation ablation and the HIFU procedure work.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Surgical operation | – | –The study aims to recruit a total of 20 patients, 10 of whom have AF and 10 who do not. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Secondary care clinic - Patients who have undergone an Epicor HIFU ablation >12 months ago
Key inclusion criteria (4 listed)
- All patients will be screened prior to enrollment in the study. The following inclusion criteria will apply to all prospective candidates:
Key exclusion criteria (2 listed)
- Patients will be excluded from the study if they meet any of the following criteria:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To document the incidence of 1 year post ablation bidirectional conduction block through the pulmonary venous cinch and mitral lines
Time frame: 1 year
Incidence of conduction block post ablation at 12 months across the pulmonary venous and mitral lines.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Sep 2017.
Related trials for Atrial Fibrillation
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruitingObservational study
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
Concomitant Procedures, Atrial Fibrillation
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Ischemic Stroke, Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Malcolm Dalrymple-Hay, MB BS, PhD principal investigator
University Hospital Plymouth NHS Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation, run by University Hospital Plymouth NHS Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Sep 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To document the incidence of 1 year post ablation bidirectional conduction block through the pulmonary venous cinch and mitral lines (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2017.